From Mechanism to Market

For 20 years Rosa has delivered insights to our clients that would be impossible to obtain in any other way.

PhysioPD Research

PhysioPD™ Research is a proprietary approach that translates the physiology, disease pathophysiology, and drug pharmacology of interest into a customized and interactive mathematical Research Platform. PhysioPD delivers credible insights that would be impossible to obtain in any other way. It is used by scientists and clinicians to clarify the connection between disease mechanisms, therapeutic interventions, and clinical outcomes. The result is that decision-makers have a dramatic increase in confidence to develop successful clinical trials and product submissions.

Learn more about PhysioPD Research
PhysioPD Research

Market Modeling

Rosa Market Modeling credibly identifies what product attributes drive physician uptake. Rosa's proprietary methods and technology can explore a breadth of product profiles and competitive scenarios that would be impossible to explore in any other way. The Market Model is a durable asset that can be used to fine-tune product features and demonstrate the potential commercial demand in a variety of current and future competitive scenarios over multiple years.

Learn more about Market Modeling

Explore our Worldwide Webinar Series

Rosa’s "Impact" webinar series is renowned for its informative discussions on the use of computer modeling and simulation within the global research and development community. Register for an upcoming webinar or download a webinar from the archives.

Explore Webinars

Recent Highlights

Rosa & Co’s 11th Consecutive Appearance at ACoP Showcases the Power of QSP Modeling with PhysioPD™ Research

Panel discussion and posters showcase how PhysioPD™ Research fundamentally improves decision making at critical steps in drug development SAN CARLOS, CA, USA, November 7, 2020 /- Rosa & Co. announced today that it will lead a panel discussion and... Read More

Model Suggests ACER-001 May Offer Improved Disease Management in Patients with Urea Cycle Disorders

NEWTON, MA – July 8, 2020 – Acer Therapeutics Announces Administration of ACER-001 in a Fasted State Increased Systemic Exposure of Phenylbutyrate in Healthy Volunteer Food Effect Study Model suggests ACER-001, Acer’s taste-masked, immediate-release ... Read More

Adamis Pharmaceuticals Announces Publication of Research with Rosa

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the publication of an article entitled “Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu rece... Read More

Webinar showcases how Rosa Market Modeling is used to optimize competitive positioning

Today, Rosa & Co. announced that Dr. Bill Brastow, Chief Technology Officer at Rosa Market Modeling, will present a webinar entitled “Driving Market Share for Healthcare Products by Integrating Market Modeling” on Wednesday, March 18. Hosted in p... Read More

"Rosa is all about doing better science"
—Christina Friedrich, PhD, Chief Engineer, PhysioPD
Learn about PhysioPD Research